Risk Factors of Outcomes Associated With Disease Progression in Patients With Atrial Fibrillation and Heart Failure (HF) Who Are Receiving a Direct Oral Anticoagulant (Rivaroxaban)

Trial Profile

Risk Factors of Outcomes Associated With Disease Progression in Patients With Atrial Fibrillation and Heart Failure (HF) Who Are Receiving a Direct Oral Anticoagulant (Rivaroxaban)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 06 Apr 2018

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Atrial fibrillation
  • Focus Therapeutic Use
  • Acronyms FARAONIC
  • Sponsors Bayer
  • Most Recent Events

    • 03 Apr 2018 Status changed from not yet recruiting to recruiting.
    • 08 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top